Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Similar articles for PubMed (Select 20129016)

1.

C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease.

Locatelli F, Mann JF, Aldigier JC, Sanz Guajardo D, Schmidt R, Van Vlem B, Sulowicz W, Dougherty FC, Beyer U.

Clin Nephrol. 2010 Feb;73(2):94-103.

PMID:
20129016
2.

The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.

Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC; BA 16528 Study Investigators.

Clin Nephrol. 2007 May;67(5):306-17.

PMID:
17542340
3.
4.

Population pharmacokinetic/pharmacodynamic model for C.E.R.A. in both ESA-naive and ESA-treated chronic kidney disease patients with renal anemia.

Chanu P, Gieschke R, Charoin JE, Pannier A, Reigner B.

J Clin Pharmacol. 2010 May;50(5):507-20. doi: 10.1177/0091270009343931. Epub 2010 Feb 23.

PMID:
20179322
5.

Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study.

de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V, Metivier F, Dougherty FC, Oguey D; BA16260 Study Invesigators.

Int J Clin Pract. 2006 Dec;60(12):1687-96. Erratum in: Int J Clin Pract. 2007 Oct;61(10):1776-7.

PMID:
17109676
6.

Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration.

Locatelli F, Villa G, de Francisco AL, Albertazzi A, Adrogue HJ, Dougherty FC, Beyer U; BA16286 Study Investigators.

Curr Med Res Opin. 2007 May;23(5):969-79.

PMID:
17519064
7.

Anemia control in renal transplant recipients receiving continuous erythropoietin receptor activator (C.E.R.A.) treatment: the AnemiaTrans Study.

Sánchez-Fructuoso AI, Ruiz JC, Torregrosa JV, González E, Gómez E, Gallego RJ, Troya MI, Jimenez C, Llamas F, Romero R, Bernis C, Crespo JF, Guirado L; AnemiaTrans Study Group.

Adv Ther. 2012 Nov;29(11):979-91. doi: 10.1007/s12325-012-0063-3. Epub 2012 Nov 13.

PMID:
23160946
8.

Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.

Sulowicz W, Locatelli F, Ryckelynck JP, Balla J, Csiky B, Harris K, Ehrhard P, Beyer U; PROTOS Study Investigators.

Clin J Am Soc Nephrol. 2007 Jul;2(4):637-46. Epub 2007 May 23.

9.

Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease.

Macdougall IC, Robson R, Opatrna S, Liogier X, Pannier A, Jordan P, Dougherty FC, Reigner B.

Clin J Am Soc Nephrol. 2006 Nov;1(6):1211-5. Epub 2006 Sep 13.

11.

Continuous erythropoietin receptor activator (Mircera) for renal anemia.

McGahan L.

Issues Emerg Health Technol. 2008 Feb;(113):1-6.

PMID:
18354858
12.

Fewer dose changes with once-monthly C.E.R.A. in patients with chronic kidney disease.

Mann JF, de Francisco A, Nassar G, Canaud B.

Clin Nephrol. 2011 Jul;76(1):9-15.

PMID:
21722600
13.

C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.

Spinowitz B, Coyne DW, Lok CE, Fraticelli M, Azer M, Dalal S, Villa G, Rosansky S, Adamis H, Beyer U; RUBRA Study Investigators.

Am J Nephrol. 2008;28(2):280-9. Epub 2007 Nov 13.

PMID:
18004064
14.

The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease.

Fliser D, Dellanna F, Koch M, Seufert J, Witzke O, Hauser IA.

Contemp Clin Trials. 2011 Nov;32(6):786-92. doi: 10.1016/j.cct.2011.06.008. Epub 2011 Jul 7. Review.

PMID:
21762788
15.
16.

[The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial].

Chen N, Qian JQ, Mei CL, Zhang AH, Xing CY, Wang L, Liu WH, Wang M, Chen JH, Liu BC, Hou FF, Chen XM, Zuo L, Shi W, Yu LB, Zhang Y.

Zhonghua Nei Ke Za Zhi. 2012 Jul;51(7):502-7. Chinese.

PMID:
22943819
17.

Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial.

Klinger M, Arias M, Vargemezis V, Besarab A, Sulowicz W, Gerntholtz T, Ciechanowski K, Dougherty FC, Beyer U.

Am J Kidney Dis. 2007 Dec;50(6):989-1000.

PMID:
18037099
19.

C.E.R.A.: pharmacodynamics, pharmacokinetics and efficacy in patients with chronic kidney disease.

Locatelli F, Reigner B.

Expert Opin Investig Drugs. 2007 Oct;16(10):1649-61. Review.

PMID:
17922628
20.

Factors related to the absence of anemia in hemodialysis patients.

Verdalles U, Abad S, Vega A, Ruiz Caro C, Ampuero J, Jofre R, Lopez-Gomez JM.

Blood Purif. 2011;32(1):69-74. doi: 10.1159/000323095. Epub 2011 Feb 24.

PMID:
21346339
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk